Suppr超能文献

开发、验证和预后评估一般人群中长期肝脏相关结局的风险评分:一项多队列研究。

Development, validation, and prognostic evaluation of a risk score for long-term liver-related outcomes in the general population: a multicohort study.

机构信息

Epidemiology, Statistics, and Prevention Institute, University of Zurich, Zurich, Switzerland.

Liver Unit Hospital Clínic, University of Barcelona, Barcelona, Catalonia, Spain; Institut D'Investigacions Biomèdiques August Pi I Sunyer, Barcelona, Catalonia, Spain; Centro de Investigación En Red de Enfermedades Hepáticas Y Digestivas, Barcelona, Spain.

出版信息

Lancet. 2023 Sep 16;402(10406):988-996. doi: 10.1016/S0140-6736(23)01174-1. Epub 2023 Aug 9.

Abstract

BACKGROUND

Liver cirrhosis is a major cause of death worldwide. Cirrhosis develops after a long asymptomatic period of fibrosis progression, with the diagnosis frequently occurring late, when major complications or cancer develop. Few reliable tools exist for timely identification of individuals at risk of cirrhosis to allow for early intervention. We aimed to develop a novel score to identify individuals at risk for future liver-related outcomes.

METHODS

We derived the LiverRisk score from an international prospective cohort of individuals from six countries without known liver disease from the general population, who underwent liver fibrosis assessment by transient elastography. The score included age, sex, and six standard laboratory variables. We created four groups: minimal risk, low risk, medium risk, and high risk according to selected cutoff values of the LiverRisk score (6, 10, and 15). The model's discriminatory accuracy and calibration were externally validated in two prospective cohorts from the general population. Moreover, we ascertained the prognostic value of the score in the prediction of liver-related outcomes in participants without known liver disease with median follow-up of 12 years (UK Biobank cohort).

FINDINGS

We included 14 726 participants: 6357 (43·2%) in the derivation cohort, 4370 (29·7%) in the first external validation cohort, and 3999 (27·2%) in the second external validation cohort. The score accurately predicted liver stiffness in the development and external validation cohorts, and was superior to conventional serum biomarkers of fibrosis, as measured by area under the receiver-operating characteristics curve (AUC; 0·83 [95% CI [0·78-0·89]) versus the fibrosis-4 index (FIB-4; 0·68 [0·61-0·75] at 10 kPa). The score was effective in identifying individuals at risk of liver-related mortality, liver-related hospitalisation, and liver cancer, thereby allowing stratification to different risk groups for liver-related outcomes. The hazard ratio for liver-related mortality in the high-risk group was 471 (95% CI 347-641) compared with the minimal risk group, and the overall AUC of the score in predicting 10-year liver-related mortality was 0·90 (0·88-0·91) versus 0.84 (0·82-0·86) for FIB-4.

INTERPRETATION

The LiverRisk score, based on simple parameters, predicted liver fibrosis and future development of liver-related outcomes in the general population. The score might allow for stratification of individuals according to liver risk and thus guide preventive care.

FUNDING

European Commission under the H20/20 programme; Fondo de Investigación Sanitaria de Salud; Instituto de Salud Carlos III; Spanish Ministry of Economy, Industry, and Competitiveness; the European Regional Development Fund; and the German Ministry of Education and Research (BMBF).

摘要

背景

肝硬化是全球范围内主要的死亡原因。肝硬化在纤维化进展的长期无症状期后发展,诊断通常发生较晚,此时会出现重大并发症或癌症。目前几乎没有可靠的工具可用于及时识别处于肝硬化风险中的个体,从而进行早期干预。我们旨在开发一种新的评分系统来识别有未来肝脏相关结局风险的个体。

方法

我们从来自六个国家的普通人群中没有已知肝脏疾病的个体的国际前瞻性队列中得出了 LiverRisk 评分,这些个体通过瞬时弹性成像进行了肝纤维化评估。该评分包括年龄、性别和六个标准实验室变量。我们根据 LiverRisk 评分的选定截断值(6、10 和 15)将个体分为四个组:最小风险、低风险、中风险和高风险。该模型的判别准确性和校准在来自普通人群的两个前瞻性队列中进行了外部验证。此外,我们在中位随访 12 年的无已知肝脏疾病参与者(英国生物库队列)中确定了该评分在预测肝脏相关结局方面的预后价值。

结果

我们纳入了 14726 名参与者:其中 6357 名(43.2%)在推导队列中,4370 名(29.7%)在第一个外部验证队列中,3999 名(27.2%)在第二个外部验证队列中。该评分在开发和外部验证队列中准确预测了肝硬度,并且优于传统的纤维化血清生物标志物,如接受者操作特征曲线下面积(AUC;0.83[95%CI 0.78-0.89])与纤维化-4 指数(FIB-4;0.68[0.61-0.75]在 10kPa)。该评分能够有效识别有肝脏相关死亡率、肝脏相关住院和肝癌风险的个体,从而可以根据肝脏相关结局的不同风险组进行分层。高危组的肝脏相关死亡率风险比为 471(95%CI 347-641),与最低风险组相比,该评分在预测 10 年肝脏相关死亡率方面的总 AUC 为 0.90(0.88-0.91),而 FIB-4 的 AUC 为 0.84(0.82-0.86)。

解释

基于简单参数的 LiverRisk 评分可预测普通人群的肝纤维化和未来肝脏相关结局的发展。该评分可能允许根据肝脏风险对个体进行分层,从而指导预防保健。

资金

欧盟 H20/20 计划;西班牙卫生研究基金会;西班牙卡洛斯三世健康研究所;西班牙经济、工业和竞争力部;欧洲区域发展基金;德国联邦教育与研究部(BMBF)。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验